Recombinant human microplasmin: Production and potential therapeutic properties

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 2, 2003, Pages 307-313

  Nagai, N ^a   Demarsin, E ^a   Van Hoef, B ^a   Wouters, S ^b   Cingolani, D ^b   Laroche, Y ^c   Collen, D ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b EUROGENTEC S A   (Belgium)

^c Thromb X   (Belgium)

Author keywords

Arterial occlusion; Ischemic stroke; Microplasmin; Thrombolysis; Thrombosis

Indexed keywords

COMPLEMENTARY DNA; MICROPLASMIN; PEPTIDE FRAGMENT; PLASMIN; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CEREBRAL ARTERY DISEASE; DISEASE MODEL; DRUG EFFECT; FIBRINOLYTIC THERAPY; GENETICS; HEMOSTASIS; HUMAN; IN VITRO STUDY; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; RABBIT; THROMBOSIS;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; HEMOSTASIS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PLASMIN; RABBITS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; THROMBOSIS;

EID: 0141673321     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00078.x     Document Type: Article

References (20)

1. Ambrus JL, Ambrus CM, Bock N et al. Clinical and experimental studies on fibrinolytic enzymes. Ann New York Acad Sci 1957; 68: 97.
2. Clifton EE. The use of plasmin in humans. Ann New York Acad Sci 1957; 68: 209-29.
3. Jensen VJ (inventor). US patent 3,950,513. Process of stabilizing therapeutically useful plasmin solutions. Novo Terapeutisk Laboratorium (assignee). Issued 13 April, 1976.
4. 2-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. Blood 2001; 97: 3086-92.
5. Nagai N,DeMolM, Lijnen HR,CarmelietP, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction. A gene targeting and gene transfer study in mice. Circulation 1999; 99: 2440-4.
6. Marder VJ, Landskroner K, Novokhatny V, Zimmerman T, Koig M, Kanouse JJ. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-45.
7. Whitefleet-Smith J, Rosen E, McLinden J, Ploplis VA, Tomlinson JE, McLean JW, Castellino FJ. Expression of human plasminogen cDNA in a baculovirus vector-infected insect cell system. Arch Biochem Biophys 1989; 271: 390-9.
8. Shi GY,Wu HL. Isolation and characterization of microplasminogen. A low molecular weight form of plasminogen. J Biol Chem 1988; 263: 17071-5.
9. Reich E, Easton T G (inventors). US patent 5,288,489. Fibrinolysis and fibrinogenolysis treatment. Orion Therapeutic Systems (assignee). Issued February, 1994.
10. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8.
11. Collen D, Nagai N, Laroche Y. Stabilized recombinant plasmin. Patent Appl UK0116702.2, 11 July, 2001.
12. Lasters I, Van Herzeele N, Lijnen HR, Collen D, Jespers L. Enzymatic properties of phage-displayed fragments of human plasminogen. Eur J Biochem 1997; 244: 946-52.
13. Forsgren M, Raden B, Israelsson M, Larrson K, Heden LO. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett 1987; 213: 254-60.
14. Welsh FA, Sakamoto T, McKee AE, Sims RE. Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse brain. J Neurochem 1987; 49: 846-51.
15. 2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 1993; 24: 1077-81.
16. Hotchkiss A, Refino C, DeGuzman L, Rigter B, Eisert W. A new pan species model for the measurement of in vivo thrombolysis. Thromb Haemost 1987; 58: 107.
17. Sakata Y, Eguchi Y, Mimuro J, Matsuda M, Sumi Y. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor. Blood 1989; 74: 2692-7.
18. Reed GL, 3rd Matsueda GR, Haber E. Inhibition of clot-bound alpha 2-antiplasmin enhances in vivo thrombolysis. Circulation 1990; 82: 164-8.
19. Nagai N, Vanlinthout I, Collen D. Comparative effects of tissue-type plasminogen activator, streptokinase and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation 1999; 100: 2541-6.
20. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, Mackenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.